BioDelivery Sciences International Release: Phase III Data on BEMA(TM) Fentanyl to be Presented at the American Society of Clinical Oncology Annual Meeting

RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) and commercial partner, Meda Pharmaceuticals, today announced they will present results from Phase III clinical studies assessing the efficacy and safety of BEMA™ Fentanyl at a poster session on May 31, 2008, during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The presentation will feature data from two Phase III clinical studies assessing the efficacy and safety of BEMA™ Fentanyl, a potential treatment for breakthrough pain (BTP) in opioid tolerant patients with cancer.